share_log

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
SEC announcement ·  04/08 09:32
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced its full-year financial results for 2023, highlighting a significant turnaround from the previous year's losses. The company reported a net income of $23.9 million for the year ended December 31, 2023, compared to a net loss of $71.7 million in the previous year. This improvement was largely due to the divestiture of Movantik and ongoing cost-reduction measures. RedHill's revenue for 2023 was $6.5 million, a decrease from $61.8 million in 2022, primarily due to the divestiture of Movantik. The company's R&D efforts are focused on opaganib and RHB-107, both in advanced clinical development for multiple indications including COVID-19 and Ebola, with U.S. government funding supporting their progression. RedHill also reported a cash balance of $6.5 million as of December 31, 2023. The company is actively pursuing strategic business transactions, including potential divestment of certain assets and/or commercial operations. CEO Dror Ben-Asher emphasized the company's transformation and clear direction, with a focus on U.S. government-funded pipeline development in underserved therapeutic areas.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced its full-year financial results for 2023, highlighting a significant turnaround from the previous year's losses. The company reported a net income of $23.9 million for the year ended December 31, 2023, compared to a net loss of $71.7 million in the previous year. This improvement was largely due to the divestiture of Movantik and ongoing cost-reduction measures. RedHill's revenue for 2023 was $6.5 million, a decrease from $61.8 million in 2022, primarily due to the divestiture of Movantik. The company's R&D efforts are focused on opaganib and RHB-107, both in advanced clinical development for multiple indications including COVID-19 and Ebola, with U.S. government funding supporting their progression. RedHill also reported a cash balance of $6.5 million as of December 31, 2023. The company is actively pursuing strategic business transactions, including potential divestment of certain assets and/or commercial operations. CEO Dror Ben-Asher emphasized the company's transformation and clear direction, with a focus on U.S. government-funded pipeline development in underserved therapeutic areas.
專業生物製藥公司RedHill Biopharma Ltd. 公佈了其2023年全年財務業績，突顯了與去年虧損相比的重大轉機。該公司報告稱，截至2023年12月31日的年度淨收入爲2390萬美元，而上一年的淨虧損爲7,170萬美元。這種改善主要歸因於Movantik的剝離和持續的成本削減措施。紅山2023年的收入爲650萬美元，較2022年的6180萬美元有所減少，這主要是由於剝離了Movantik。該公司的研發工作側重於奧帕加尼布和 RHB-107，兩者均用於包括 COVID-19 和埃博拉在內的多種適應症的高級臨床開發，美國政府的資助支持其進展。RedHill還報告稱，截至2023年12月31日，現金餘額爲650萬美元。該公司正在積極進行戰略業務交易，包括可能撤資某些資產和/或商業業務。首席執行官德羅爾·本·阿舍爾強調了公司的轉型和明確的方向，重點是美國政府資助的服務不足的治療領域的管道開發。
專業生物製藥公司RedHill Biopharma Ltd. 公佈了其2023年全年財務業績，突顯了與去年虧損相比的重大轉機。該公司報告稱，截至2023年12月31日的年度淨收入爲2390萬美元，而上一年的淨虧損爲7,170萬美元。這種改善主要歸因於Movantik的剝離和持續的成本削減措施。紅山2023年的收入爲650萬美元，較2022年的6180萬美元有所減少，這主要是由於剝離了Movantik。該公司的研發工作側重於奧帕加尼布和 RHB-107，兩者均用於包括 COVID-19 和埃博拉在內的多種適應症的高級臨床開發，美國政府的資助支持其進展。RedHill還報告稱，截至2023年12月31日，現金餘額爲650萬美元。該公司正在積極進行戰略業務交易，包括可能撤資某些資產和/或商業業務。首席執行官德羅爾·本·阿舍爾強調了公司的轉型和明確的方向，重點是美國政府資助的服務不足的治療領域的管道開發。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息